The immune checkpoint inhibitors (ICI) targeting programmed death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) have become a standard treatment option for patients with advanced NSCLC who do not carry targetable mutations, however their efficacy in patients harbouring K-RAS mutations was unknown. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.